Overview of Treatment Trials: Early Baseline Clinical and MRI Data of the PROMiSe Trial
Primary progressive multiple sclerosis (PPMS) is the least common clinical disease phenotype exhibited by MS patients. Current international consensus definitions of the various disease phenotypes demand that patients with PPMS have a progressive disease from onset and a clinical course without discernible attacks . Some minor amount of improvement or worsening is allowed, but episodes that fit most modern trial definitions of acute relapses eliminate patients from this subtype and consign them to either secondary progressive or progressive relapsing MS categories, depending upon whether the attack occurred prior to or following the onset of their progressive neurologic dysfunction. Approximately 15% of MS patients have a progressive disease at onset, but nearly one-third of these will experience a clinical relapse. Thus, only 10% of all MS patients have PPMS. It is likely that some of these patients fail to recall remote episodes of neurologic dysfunction that may or may not have been attended by physicians or resulted in a formal diagnosis. Such cases of cryptic secondary progressive or “transitional” MS  may contaminate to some extent any cohort of rigorously defined PPMS patients. Further complicating our understanding of this clinical phenotype is the common use of the term “chronic progressive MS” to describe patient cohorts with secondary progressive, progressive relapsing, or PPMS.
KeywordsExpand Disability Status Scale Glatiramer Acetate Cerebral Spinal Fluid Expand Disability Status Scale Score Primary Progressive Multiple Sclerosis
Unable to display preview. Download preview PDF.
- 1.Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907–911Google Scholar
- 5.Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-la in MS (SPECTRIMS) Study Group (2001) Randomized controlled trial of interferon-beta-la in secondary progressive MS: Clinical results. Neurology 56:1496–1504Google Scholar
- 7.Weinshenker BG, Bass B, Rice GP et al (1989) The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112:133–146Google Scholar
- 10.McDonnell GV, Hawkins SA (1998) Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK. J Neurol Neurosurg Psychiatry 64:451–6454Google Scholar
- 12.McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 50:121–127Google Scholar
- 14.Cottrell DA, Kremenchutzky M, Rice GP et al (1999) The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 122:625–639Google Scholar
- 16.Wolinsky JS, Narayana PA, Noseworthy JH et al (2000) Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators. Neurology 54:1734–1741Google Scholar
- 17.Wolinsky JS, Narayana PA, Johnson KP, and the Copolymer 1 Multiple Sclerosis Study Group and the MRI Analysis Center (2001) United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Mult Scler 7:33–41Google Scholar
- 18.Noseworthy JH, Wolinsky JS, Lublin FD et al (2000) Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology 54:1726–1733Google Scholar